C4b-binding protein (C4BP) is an important component in the regulation of the complement system and also binds the anticoagulant vitamin K-dependent protein S. These activities are performed by distinct, although structurally related, polypeptides of 70 kDa (alpha chain) and 45 kDa (beta chain), respectively. In this report we have investigated the genetic relationships between these polypeptides. Using pulsed field gel electrophoresis analysis we demonstrate that the genes coding for the alpha (C4BP alpha) and beta (C4BP beta) chains are closely linked within the regulator of complement activation gene cluster. In addition, we have determined that the 3' end of the C4BP beta gene lies 3.5-5 kilobases from the 5' end of the C4BP alpha gene. These findings support the concept that the C4BP alpha and C4BP beta genes are the result of a gene duplication event.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC54149 | PMC |
| http://dx.doi.org/10.1073/pnas.87.12.4529 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Nilotinib treatment outcomes in autosomal dominant spinocerebellar ataxia over one year.
Sci Rep
July 2024
Department of Neurology, Seoul National University College of Medicine, Seoul National University Hospital, 101, Daehangno, Jongno-gu, Seoul, 03080, Republic of Korea.
Article Synopsis
- A study assessed the 1-year treatment of nilotinib in patients with autosomal dominant spinocerebellar ataxia (ADSCA), focusing on treatment efficacy and safety.
- Although the average ataxia severity, measured by the SARA score, did not significantly improve for the overall group, 62.5% of participants were considered 'responsive' based on score improvements.
- Serum proteomic analysis identified specific proteins that may help predict which patients are likely to respond to nilotinib, suggesting potential pathways for improving treatment strategies for ADSCA.
Identification of as biomarker associated with immune infiltration and prognosis in breast cancer.
Transl Cancer Res
January 2024
Department of General Surgery, The Second Affiliated Hospital of Shantou University Medical College, Shantou, China.
Background: is a gene that encodes the C4BP protein α chain and is involved in the complement system. is regarded as a new biomarker for cancer, especially for non-small cell lung cancer and ovarian cancer. However, its role in breast cancer (BC) has not yet been determined.
View Article and Find Full Text PDFThe Complement Component 4 Binding Protein α Gene: A Versatile Immune Gene That Influences Lipid Metabolism in Bovine Mammary Epithelial Cell Lines.
Int J Mol Sci
February 2024
The Key Laboratory of Animal Genetic Resource and Breeding Innovation, College of Coastal Agricultural Sciences, Guangdong Ocean University, Zhanjiang 524088, China.
Complement component 4 binding protein α () is an immune gene which is responsible for the complement regulation function of by binding and inactivating the Complement component C4b () component of the classical Complement 3 () invertase pathway. Our previous findings revealed that was differentially expressed by comparing the transcriptome in high-fat and low-fat bovine mammary epithelial cell lines (BMECs) from Chinese Holstein dairy cows. In this study, a gene knockout BMECs line model was constructed via using a CRISPR/Cas9 system to investigate the function of in lipid metabolism.
View Article and Find Full Text PDFThe Complement System and C4b-Binding Protein: A Focus on the Promise of C4BPα as a Biomarker to Predict Clopidogrel Resistance.
Mol Diagn Ther
March 2024
Division of Clinical Pharmacology, General Clinical Research Center, Nanjing First Hospital, Nanjing Medical University, 68 Changle Road, Nanjing, 210006, China.
The complement system plays a dual role in the body, either as a first-line defense barrier when balanced between activation and inhibition or as a potential driver of complement-associated injury or diseases when unbalanced or over-activated. C4b-binding protein (C4BP) was the first circulating complement regulatory protein identified and it functions as an important complement inhibitor. C4BP can suppress the over-activation of complement components and prevent the complement system from attacking the host cells through the binding of complement cleavage products C4b and C3b, working in concert as a cofactor for factor I in the degradation of C4b and C3b, and consequently preventing or reducing the assembly of C3 convertase and C5 convertase, respectively.
View Article and Find Full Text PDFC4BP(β-)-mediated immunomodulation attenuates inflammation in DSS-induced murine colitis and in myeloid cells from IBD patients.
Pharmacol Res
November 2023
Immune-inflammatory Processes and Gene Therapeutics Group, Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet de Llobregat, 08908 Barcelona, Spain. Electronic address:
The most recent and promising therapeutic strategies for inflammatory bowel disease (IBD) have engaged biologics targeting single effector components involved in major steps of the immune-inflammatory processes, such as tumor necrosis factor, interleukins or integrins. Nevertheless, these molecules have not yet met expectations regarding efficacy and safety, resulting in a significant percentage of refractory or relapsing patients. Thus, novel treatment options are urgently needed.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!